ライフサイエンスコーパス: GlaxoSmithKline

1 se of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

2 egistry maintained by the drug manufacturer (GlaxoSmithKline).

3 itute of Mental Health, ViiV Healthcare, and GlaxoSmithKline.

4 titute of Mental Health, and ViiV Healthcare-GlaxoSmithKline.

5 chard Therapeutics, Fondazione Telethon, and GlaxoSmithKline.

6 -Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline.

7 itute of Allergy and Infectious Diseases and GlaxoSmithKline.

8 identical to those of DELSM manufactured by GlaxoSmithKline.

9 ion, the Roger de Spoelberch Foundation, and GlaxoSmithKline.

10 National Institute for Health Research, GlaxoSmithKline.

11 ubunit protein vaccine candidate provided by GlaxoSmithKline.

12 iclovir was provided for trial 3 for free by GlaxoSmithKline.

13 Hospital Center and by a research grant from GlaxoSmithKline.

14 ntroduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines aga

15 se (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged surviva

16 t reverse transcriptase inhibitor (retrovir, GlaxoSmithKline, 1987).

17 Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine req

18 d with recombinant ASP-2 formulated with the GlaxoSmithKline Adjuvant, AS03.

19 efficacy studies (assessing the 3-component GlaxoSmithKline and 5-component Sanofi-Pasteur formulati

20 Two live oral vaccines being prepared by GlaxoSmithKline and Merck have completed large-scale cli

21 d to model 5-HT type 3 antagonist (Lotronex, GlaxoSmithKline) and 5-HT type 4 agonist (Zelnorm, Novar

22 received oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline) and one patient with impaired renal fun

23 UK Medical Research Council, GlaxoSmithKline, and British Heart Foundation.

24 Italian Telethon Foundation, GlaxoSmithKline, and Orchard Therapeutics.

25 0 through collaboration between AstraZeneca, GlaxoSmithKline, and the University of Cambridge, with C

26 misation list that was computer generated at GlaxoSmithKline, and was stratified, in a block size of

27 oratories in the nonprofit sector, Merck and GlaxoSmithKline are developing commercial versions of th

28 United Kingdom (Grant Number G0700654); and GlaxoSmithKline as part of an MRC-CASE studentship (gran

29 Council (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation

30 P vaccine (DTaP-Hib-HepB-IPV, Infanrix hexa, GlaxoSmithKline, Australia) at approximately 6 weeks old

31 ne at 18 months old (DTaP-IPV, Infanrix-IPV, GlaxoSmithKline, Australia).

32 GlaxoSmithKline, Bill & Melinda Gates Foundation, Partne

33 and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).

34 GlaxoSmithKline Biologicals SA and PATH Malaria Vaccine

35 n influenza A(H1N1)pdm09 vaccine (Pandemrix; GlaxoSmithKline Biologicals).

36 formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals).

37 Vaccine Group, University of Oxford, UK; and GlaxoSmithKline Biologicals, Belgium.

38 ion to product-specific results for Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) or Rota

39 NIHR Oxford Biomedical Research Centre and GlaxoSmithKline Biologicals.

40 Vaccine was provided by GlaxoSmithKline Biologicals.

41 is Vaccines and Diagnostics), AS03 and AS04 (GlaxoSmithKline Biologics), AF03 (Sanofi), and liposomes

42 ception occurring after Rotarix vaccination (GlaxoSmithKline Biologics, Research Triangle Park, North

43 l population structure and vaccine (Bexsero, GlaxoSmithKline, Brentford, Middlesex, UK) antigen varia

44 ivated protein kinase inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United Kingdom), which reduc

45 oehringer Ingelheim, Novartis, and Sepracor; GlaxoSmithKline; Centers for Medicare and Medicaid Servi

46 1:1-134, 2009 and GlaxoSmithKline clinical documents related to acyclovir.

47 We searched MEDLINE, the GlaxoSmithKline clinical trials register, the US Food an

48 eidentified individual participant data from GlaxoSmithKline clinical trials were obtained through Cl

49 cted at a specialist early psychosis clinic, GlaxoSmithKline Clinical Unit, and magnetic resonance im

50 djuvanted H1N1 influenza vaccine (Pandemrix [GlaxoSmithKline]) during pregnancy.

51 attenuated, oral rotavirus vaccine (Rotarix, GlaxoSmithKline) efficacy trial conducted among infants

52 Additionally, the GlaxoSmithKline family of adjuvants AS01B, AS02A, and AS

53 ized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N = 10,743 pa

54 nal Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim,

55 dation, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Insitro, Janssen Neurosc

56 es and Diagnostics division (now part of the GlaxoSmithKline group of companies), Wellcome Trust UK,

57 es and Diagnostics division, now part of the GlaxoSmithKline group of companies.

58 omized controlled trials (RCTs) conducted by GlaxoSmithKline (GSK) and the NCIC Clinical Trials Group

59 distributed to more than 300 laboratories by GlaxoSmithKline (GSK) between 2011 and 2015 and by SGC-U

60 ical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studie

61 gs for Neglected Diseases initiative (DNDi), GlaxoSmithKline (GSK), and the University of Dundee.

62 pounds with known MOA previously reported by GlaxoSmithKline (GSK).

63 me Vice President, Translational Research at GlaxoSmithKline (GSK).

64 tween the University of Nottingham (UoN) and GlaxoSmithKline (GSK).

65 says of 631 diverse chemicals proprietary to GlaxoSmithKline (GSK).

66 women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investig

67 The CRAC channel blocker developed by GlaxoSmithKline, GSK-7975A, inhibited store-operated Ca(

68 GlaxoSmithKline has recently disclosed the results of a

69 ew Cruzipain inhibitory scaffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and

70 d at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) have allowed us to analyze the relative

71 Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversit

72 independent case-control studies of MDD: the GlaxoSmithKline-High-Throughput Disease-specific target

73 (6/21 [29%]), intradermal IPV (9/16 [56%]), GlaxoSmithKline intramuscular IPV (19/22 [86%]), and Pan

74 egative, 42 (100%) of 42 seroconverted after GlaxoSmithKline intramuscular IPV, and 24 (59%) of 41 af

75 al Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire Vaudoise.

76 ction of a replacement MMR vaccine (Priorix; GlaxoSmithKline, London, United Kingdom) in 1998, active

77 ritish Heart Foundation, Cancer Research UK, GlaxoSmithKline, Medical Research Council, and Wellcome

78 number G1000417/94909), ICON, Astra Zeneca, GlaxoSmithKline, Medicines Evaluation Unit).

79 GlaxoSmithKline, Medicines for Malaria Venture.

80 GlaxoSmithKline; National Institutes of Health; and Mayo

81 ger Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or

82 l-dose IPV from two different manufacturers (GlaxoSmithKline or Panacea).

83 al-dose inactivated poliovirus vaccine (IPV, GlaxoSmithKline), or intramuscular full-dose IPV from tw

84 Rotarix (GlaxoSmithKline) oral rotavirus vaccine is licensed as 2

85 and Genomic Epidemiology (ENGAGE) and Oxford-GlaxoSmithKline (Ox-GSK) consortia to follow up the 15 m

86 ared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice dai

87 FabI inhibitors began with screening of the GlaxoSmithKline proprietary compound collection, which i

88 rough high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection.

89 ibitors from a high throughput screen of the GlaxoSmithKline proprietary compound collection.

90 GlaxoSmithKline, Prosensa Therapeutics BV (a subsidiary

91 GlaxoSmithKline R&D and the Medical Research Council.

92 one-based interactive voice-response system (GlaxoSmithKline Registration and Medication Ordering Sys

93 Randomisation was done by the GlaxoSmithKline Registration and Medication Ordering Sys

94 Randomisation was done by the GlaxoSmithKline Registration/Medication Ordering System

95 y assigned to standard therapy (Nicoderm CQ [GlaxoSmithKline, Research Triangle Park, North Carolina]

96 d (1:1) to receive an HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart, Belgium) or a control hepati

97 s A vaccine (modified preparation of Havrix, GlaxoSmithKline, Rixensart, Belgium).

98 Individual-level data on 5074 infants in 9 GlaxoSmithKline Rotarix Phase 2/3 clinical trials from 1

99 ree-step asymmetric and racemic syntheses of GlaxoSmithKline's highly potent PDE IVb inhibitor 1 were

100 GlaxoSmithKline's Investigator Sponsored Studies Program

101 Pooled, individual-level data from GlaxoSmithKline's Phase II and III clinical trials of th

102 ncluding stratification, was generated using GlaxoSmithKline's RandAll software.

103 GlaxoSmithKline scientists have successfully optimized a

104 enter, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

105 iversity Research Foundation, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Wellcome Trust, UK Me

106 We established the Oxford-GlaxoSmithKline study (Ox-GSK) to perform a genome-wide

107 everal examples (use cases) from programs at GlaxoSmithKline that demonstrate the utility of mTPA thr

108 ata for a large set of compounds reported by GlaxoSmithKline (the Tres Cantos AntiMalarial Set, TCAMS

109 Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Coun

110 From the GlaxoSmithKline trial registry, we selected randomised,

111 nt trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT0076947

112 recombinant shingles vaccine (RZV; Shingrix, GlaxoSmithKline) vaccination program in adults aged >=65

113 The GlaxoSmithKline vaccine has been licensed in Mexico and

114 ation schedule was generated by means of the GlaxoSmithKline validated randomisation software RANDALL

115 Randomisation was generated using the GlaxoSmithKline-validated randomisation software RANDALL

116 000 copies per mL) and sex at birth and used GlaxoSmithKline-verified randomisation software (RandAll

117 al virus (RSV) vaccine for older adults from GlaxoSmithKline was the first RSV vaccine approved by th

118 Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introduced in Kenya in July 2014 a

119 ritish Heart Foundation, Cancer Research UK, GlaxoSmithKline, Wellcome Trust, Medical Research Counci